Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FES-PET imaging of fulvestrant effect in metastatic ER-positive breast cancer
2010-023987-41Phase 2Active
- Sponsor
- University Medical Center Groningen
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fulvestrant in breast cancer, sponsored by University Medical Center Groningen. Primary endpoint: Feasibility of FES-PET imaging of ER binding site availability during fulvestrant therapy. Started May 2011; status: active.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-023987-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023987-41.